Clinical trials: Gastrointestinal Cancer
Breast Cancer, Benign Breast Condition
ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health
AUDIBLE is a multi-site, clinical study conducted in the United States aimed at gathering data on 3D Automated Breast Ultrasound imaging using the iSono Health ATUSA system.
- Conditions
- Breast Cancer, Benign Breast Condition, Breast Fibroadenoma, Breast Neoplasms
- Trial name
- AUDIBLE (NCT07505797)
- Testing
- ATUSA 3D Automated Breast Ultrasound System
- Where
- 2 sites in United States
- Volunteers
- 800 people
- Sponsor
- iSono Health, Inc.
Ovarian Cancer, Head and Neck Cancer
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.
- Conditions
- Ovarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer
- Trial name
- NCT05001347
- Testing
- TJ004309
- Where
- 15 sites in United States
- Volunteers
- 25 people
- Sponsor
- I-Mab Biopharma US Limited
Colon Cancer
BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
This is a randomized, parallel, multi-center, single-blind study, comparing BLI850 to an FDA approved bowel preparation in adult subjects undergoing colonoscopy.
- Trial name
- NCT00756548
- Testing
- BLI850, polyethylene glycol 3350 based bowel preparation
- Where
- 12 sites in United States
- Volunteers
- 386 people
- Sponsor
- Braintree Laboratories
Pancreatic Carcinoma
Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
The purpose of this study is to demonstrate that preoperative biliary drainage using self-expanding metal stents (SEMS) does not negatively impact overall surgical outcomes in patients undergoing pancreaticoduodenectomy for…
- Trial name
- NCT01774019
- Testing
- WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
- Where
- 11 sites in United States, Australia and 7 more
- Volunteers
- 284 people
- Sponsor
- Boston Scientific Corporation
Colorectal Cancer
LYL273 for Patients With Relapsed or Refractory mCRC
This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.
- Trial name
- CARABiNER (NCT05319314)
- Testing
- LYL273
- Where
- 5 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lyell Immunopharma, Inc.
Pancreatic Cancer, Metastatic Pancreatic Cancer
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic).
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT07409272
- Testing
- Setidegrasib, Oxaliplatin, Leucovorin
- Where
- 79 sites in United States, China and 4 more
- Volunteers
- 614 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Colorectal Cancer (Diagnosis)
Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study
The primary objective of this study is to evaluate a blood-based screening test for Colorectal Cancer (CRC).
- Trial name
- CLEAR (NCT07479381)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Harbinger Health
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Safety Run-in Cohort (cohort 1): 10 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days.
- Trial name
- NCT05223816
- Testing
- VG161, Nivolumab Injection [Opdivo]
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Virogin Biotech Canada Ltd
Hepatocellular Carcinoma
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.
- Trial name
- NCT05320692
- Testing
- TACE+Camrelizumab+Apatinib mesylate, TACE
- Where
- China
- Volunteers
- 423 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Carcinoma, Hepatocellular
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
This is a study to investigate the potential clinical benefit of refametinib when given in combination with sorafenib as first line treatment in patients with unresectable or metastatic HCC carrying a RAS mutation.
- Trial name
- NCT01915602
- Testing
- Refametinib (BAY86-9766), Sorafenib (BAY43-9006)
- Where
- 79 sites in United States, Austria and 19 more
- Volunteers
- 14 people
- Sponsor
- Bayer
Gastrointestinal Stromal Tumors
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
The purpose of this study is to collect and assess long-term safety of nilotinib in patients who are on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs study and are benefiting from…
- Trial name
- NCT01863745
- Testing
- nilotinib
- Where
- 11 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Healthy
Collection and Distribution of Biospecimens for Novel Research
iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with…
- Conditions
- Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases
- Trial name
- NCT05080907
- Testing
- Observational
- Where
- 7 sites in United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- iSpecimen Inc
Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Approximately 36 DLT-evaluable subjects will be enrolled in this study. The locations of the study will be in the United States, Australia, Europe and Switzerland.
- Trial name
- NCT03256344
- Testing
- Talimogene Laherparepvec, Atezolizumab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 36 people
- Sponsor
- Amgen
Colorectal Neoplasms
EffectiveNess of Low Dose Aspirin in GastrointEstinal Cancer Prevention - Taiwan
The study evaluates the protective effect of low-dose aspirin use on gastrointestinal cancers (colorectal, esophageal and gastric cancers) in long-term users, episodic users and non-users of aspirin in Taiwan.
- Trial name
- ENgAGE-Taiwan (NCT03579732)
- Testing
- Aspirin (Acetylsalicylic Acid, BAYE4465), No drug
- Where
- Taiwan
- Volunteers
- 4,710,504 people
- Sponsor
- Bayer
Colon Cancer
NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
The main objective of the trial is to document the safety of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin based regimen in patients with metastatic colorectal cancer not amenable to any…
- Trial name
- NCT00675012
- Testing
- NGR-hTNF, Oxaliplatin, capecitabine
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- AGC Biologics S.p.A.
Metastatic Pancreatic Cancer
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
This study is a multicenter, open-label, uncontrolled study to investigate the tolerability and safety of ONO-4578, ONO-4538, and standard of care in combination as first-line treatment in patients with metastatic pancreatic…
- Trial name
- NCT06538207
- Testing
- ONO-4578, ONO-4538, Oxaliplatin
- Where
- 9 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Bowel Dysfunction, Constipation
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one 2 alvimopan arms, or to placebo.
- Trial name
- NCT00256932
- Testing
- alvimopan
- Where
- 200 sites in United States, Austria and 8 more
- Volunteers
- 518 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pancreatic Cancer
Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without exatecan mesylate in treating pancreatic…
- Trial name
- NCT00023972
- Testing
- exatecan mesylate, gemcitabine hydrochloride
- Where
- 74 sites in United States, Canada and 1 more
- Sponsor
- Daiichi Sankyo
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic…
- Trial name
- NCT04246177
- Testing
- Lenvatinib, Pembrolizumab, TACE
- Where
- 205 sites in United States, Australia and 25 more
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
- Conditions
- Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer
- Trial name
- PACT (NCT02791334)
- Testing
- LY3300054, Ramucirumab, Abemaciclib
- Where
- 14 sites in United States, Belgium and 5 more
- Volunteers
- 164 people
- Sponsor
- Eli Lilly and Company